ReviewDermatologic therapy2021
Topical beta-blockers in dermatologic therapy.
Review in Dermatologic therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 31 citations in OpenAlex.
- Fractional COLasers in medical science · 2025Trial
- A Case of Slow Progressive Cutaneous Angiomatosis on a Cat Metatarsal Pad Treated by a Topical Beta-Blocker.Veterinary dermatology · 2026Article
- A chitosan-based thermosensitive hydrogel incorporating propranolol nanoparticles to promote early osseointegration and peri-implant soft-tissue healing.RSC advances · 2026Article
- Research progress on the use of beta-blockers in the progression prevention, and treatment of retinopathy of prematurity.Frontiers in pediatrics · 2026Review
- Topical Timolol in the Treatment of Hemodialysis Tunneled Catheter Exit-Site Pyogenic Granuloma.Kidney international reports · 2025Article
- The Evaluation, Diagnosis, and Management of Infantile Hemangiomas-A Comprehensive Review.Journal of clinical medicine · 2025Review
- Infantile Hemangioma: A Cross-Sectional Observational Study.Life (Basel, Switzerland) · 2023Article
- A successful treatment with oral beta-blocker: A case report of a recurrent pyogenic granuloma in the external auditory canal.SAGE open medical case reports · 2023Article
- Caged-carvedilol as a new tool for visible-light photopharmacology of β-adrenoceptors in native tissues.iScience · 2022Article
- Update on Treatment of Infantile Hemangiomas: What's New in the Last Five Years?Frontiers in pharmacology · 2022Review
- Topical beta-blockers in dermatologic therapy.Dermatologic therapy · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An increasing use of beta-blockers in dermatology has been described over the last 10 years, despite the fact that their use in diseases other than infantile hemangiomas is off-label. This review discusses the emerging role of topical beta-blockers in the treatment of infantile hemangioma, but also pyogenic granuloma, Kaposi sarcoma, wounds and nail paronychia. Data in literature demonstrate that topical beta-blockers are a safe and valid therapeutic option in numerous cutaneous diseases. Side effects are mainly restricted to the application site. Further studies and randomized trials may contribute to reinforce the role of topical beta-blockers in the dermatological armamentarium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.